Actinium Pharmaceuticals, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Actinium announced four patent issuances/advancements for Actimab-A (US patents for solid tumors expiring 2043, low-blast AML expiring 2039, Canadian applications for venetoclax and CLAG-M combinations entering pre-grant/allowed status), plus an additional manufacturing source for NCI-CRADA and company-sponsored studies with milestones in H2 2026–2027. NYSE Regulation granted a compliance plan period through November 27, 2027 (maximum available), after the company failed to meet continued listing standards; stock remains listed during this period subject to compliance monitoring.
Why this rating
Patent extensions to 2043 are strategically valuable but routine in biotech; manufacturing capacity addition supports pipeline but unquantified. NYSE delisting risk materially threatens a $43.7M-cap company's survival and funding; 16-month reprieve is critical but not resolution.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.